Report Library
All Reports
HER2+ Breast Cancer KOL Interview – US, West Coast
March 03, 2020
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
| Indications Covered: | HER2+ Breast Cancer |
Additional Resources:
- HER2+ Breast Cancer KOL Interview – UK
- Datamonitor Healthcare Oncology Disease Analysis: HER2+ Breast Cancer
- 2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
- 2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
- Datamonitor Healthcare Breast Cancer KOL Interview – San Antonio Breast Cancer Symposium
- 2018 Biomedtracker Datamonitor Healthcare Post-ESMO Report